Determination of Residual Anticoagulatory Effects of Fondaparinux

2014-07-23 21:09:35 | BioPortfolio


The purpose of this study is to determine residual anticoagulatory effects of a prophylactic or therapeutic fondaparinux treatment i.e. prior to surgery/intervention, after pause of therapy etc.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Anticoagulant Prophylaxis/Therapy


J.W. Goethe University Hospital Frankfurt/M.
Frankfurt am Main




Johann Wolfgang Goethe University Hospitals

Results (where available)

View Results


Published on BioPortfolio: 2014-07-23T21:09:35-0400

Clinical Trials [451 Associated Clinical Trials listed on BioPortfolio]

Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy

This study will evaluate bleeding risk and differences in outcomes in patients receiving and not receiving anticoagulant or antiplatelet therapy

Anticoagulant Therapy During Pacemaker Implantation

There are no established guidelines regarding interruption of warfarin anticoagulant therapy prior to surgical implantation of cardiac pacemakers. Continuing the anticoagulant could potent...

Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism

The main objective of the study is to develop or validate a clinical prediction rule for major bleeding in patients on oral anticoagulant therapy who have been safely anticoagulated witho...

PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy

Approximately 5 to 8% of patients undergoing percutaneous coronary interventions requires chronic anticoagulant therapy due to atrial fibrillation or other clinical entities. There are man...

Evaluation of Patient's Knowledge of Their NACO Treatment

More than one million of patient receive anti vitamine K treatment which is the main cause of hospitalization. About 50 000 patient receive direct oral anticoagulant . The aim is to evalu...

PubMed Articles [9176 Associated PubMed Articles listed on BioPortfolio]

Impact of non-anticoagulant therapy on patients with sepsis-induced disseminated intravascular coagulation: A multicenter, case-control study.

Anticoagulant therapy for patients with sepsis is not recommended in the latest Surviving Sepsis Campaign guidelines, and non-anticoagulant therapy is the global standard treatment approach at present...

Anticoagulant therapy and prognosis in patients with CHF and AF in the setting of real-life clinical practice.

Prevalence of atrial fibrillation (AF) grows with the increase in CHF FC and reaches 45% in III-IV FC CHF. With an adequate anticoagulant (AC) therapy, the risk of thromboembolic complications does no...

When can we stop anticoagulation in patients with cancer-associated thrombosis?

The optimal duration of anticoagulant therapy in patients with cancer-associated venous thromboembolism (VTE) is unknown. Without well-designed studies evaluating the efficacy, safety, and cost-effect...

Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: outcome and risk factors for late CMV disease.

Anti-thymocyte globulin (ATG) therapy is a risk factor for CMV disease in renal transplant (RTx) recipients and therefore antiviral prophylaxis is commonly used. We evaluated the outcome of our curren...

Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment.

Heparin therapy and prophylaxis may be accompanied by bleeding and thrombotic complications due to individual responses to treatment. Dosage control based on standard laboratory assays poorly reflects...

Medical and Biotech [MESH] Definitions

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Use of HIRUDINS as an anticoagulant in the treatment of cardiological and hematological disorders.

An enzyme fraction from the venom of the Malayan pit viper, Agkistrodon rhodostoma. It catalyzes the hydrolysis of a number of amino acid esters and a limited proteolysis of fibrinogen. It is used clinically to produce controlled defibrination in patients requiring anticoagulant therapy. EC 3.4.21.-.

Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.

Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS.

More From BioPortfolio on "Determination of Residual Anticoagulatory Effects of Fondaparinux"

Quick Search


Searches Linking to this Trial